BACK TO NEWSROOM
THE EVERY CO. CRACKS OPEN NEW HEADQUARTERS, EXPANDING CRUCIAL ON-SITE R&D AND POSITIONING FOR A BETTER FOOD FUTURE
- 49,000 sq.-ft. HQ is ideal environment for creating the proteins of tomorrow, today
- “The Hatchery” anchors expanded on-site R&D fermentation capacity, driving vital research
- State-of-the-art, custom-designed food lab powers in-house development of next-gen foods
April 5, 2023
DALY CITY, CA, April 5, 2023 --The EVERY Company ("EVERY®"), a trailblazer in animal-free protein production, announced it has moved into a state-of-the-art new headquarters optimized for onsite R&D, product innovation, and collaboration toward the production of next-generation foods. A ribbon-cutting ceremony today commemorated EVERY’s latest milestone, the latest in a series of developments that position the food tech leader for further growth and leadership in accelerating a transition to animal-free protein.
“This tremendous new space is the perfect home for EVERY’s next chapter, as we continue to develop world’s-first innovations in animal-free protein performance and products,” said EVERY® Co-Founder and CEO Arturo Elizondo.
EVERY’s purpose-built new HQ combines essential on-site biotech laboratory needs with built-for-growth office space. Each business need was carefully considered in designing the HQ, ensuring upstream R&D, recipe and application development, product demonstration and convening needs are met. A 60% lab space/40% office space split optimizes for on-site R&D and biotech business requirements, while dedicated sensory testing space optimizes in-house development of next-gen foods. The move ensures EVERY is well positioned to focus on product optimization, team collaboration and commercial acceleration to grow sustainably in the years to come.
Founded in 2014, EVERY leverages know-how of food technology and flavor to help power a more sustainable, healthy and resilient food system. At a time when companies across industries are contracting—and the climate emergency is accelerating—EVERY is doubling down on essential infrastructure, for sustained growth. The first company globally to commercialize animal-free egg proteins, EVERY is rapidly advancing against the backdrop of an historic avian flu and egg shortage, underscoring the urgent need for its products and pacesetting technology platform.
The anchor tenant with naming rights at GENESIS Station—a seminal new tailor-built biotech hub alongSanFrancisco’s 280 corridor—EVERY, and economic development coalescing in Greater San Francisco’s southwestern region. With its new HQ functioning as a compelling hub for collaboration, EVERY is well positioned to attract the brightest, most essential talent to fortify competitive advantage and excellence while continuing to expand its commercialization journey, working alongside brands to bring foods to market that set the table for a better tomorrow.
ABOUT THE EVERY COMPANY
The EVERY Co. (formerly Clara Foods) exists to accelerate the world’s transition to animal-free protein. Based in Daly City, EVERY combines industry-leading expertise in food technology and flavor to enable the foods of tomorrow, today, for the world’s global food and beverage industries.
Led by Co-Founder and Chief Executive Officer Arturo Elizondo, EVERY uses precision fermentation to brew nature-equivalent animal proteins that taste and function like the originals. The company’s portfolio includes EVERY PepsinTM and the world’s first animal-free ‘nearly invisible’ proteins—EVERY ProteinTM and EVERY EggWhiteTM—with more innovations to come. EVERY is scaling up production in partnership with BioBrew from AB In Bev, the world’s largest fermentation company, while continuing to chart the course toward a more resilient and transformative tomorrow.
Dive into the latest collaboration at TheEVERYCompany.com/PulpXEVERY, and engage on Instagram and LinkedIn.
EVERY is a registered trademark of The EVERY Company.
ABOUT PHASE 3 REAL ESTATE PARTNERS, INC
Phase 3 Real Estate Partners, Inc., (''Phase 3'') develops premier ready to occupy research and development facilities in the major innovation clusters of the United States. Phase 3's focus on delivering the highest quality space with accelerated speed to occupancy within these key geographies allows companies to immediately pursue their scientific goals. The Phase 3 team delivers a clean, modern design aesthetic, the right combination of amenities to create community and appropriate infrastructure to meet the needs of the companies who call our facilities home. The firm's expertise in development, construction and management of life science facilities results in a strong partnership between our tenants and our team. Phase 3's current portfolio consists of nearly 4.5 million square feet and is growing in San Diego, San Francisco and Boston.
GENESIS Station is a project of Phase 3.
BACK TO NEWSROOM